BioSpace News Archive

Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI) announced today certain unaudited preliminary results for the fourth quarter and full-year 2022.

Primordial Genetics, Inc., a synthetic biology company, announced the launch of its proprietary RNA polymerases to advance safe, viable mRNA-based vaccines and therapeutics.

Sonex Health, a leader in the ultrasound-guided treatment of common orthopedic syndromes affecting the extremities, including entrapment neuropathies and tendinopathies, today announced the completion of patient enrollment in its clinical trial comparing ultrasound guided carpal tunnel release (CTR) versus traditional surgical mini-open CTR release (TUTOR).

The FDA has granted an orphan drug designation (ODD) to GIVI-MPC, a first-in-class IPS stem cell therapeutic for the treatment of patients with Duchenne Muscular Dystrophy.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced an update on preliminary safety and efficacy data from its ongoing FORTIS Phase1/2 clinical trial evaluating the safety, tolerability and exploratory efficacy of investigational AT845 in adults with late-onset Pompe disease (LOPD).

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its fourth quarter and full year 2022 financial and operating results after the close of U.S. financial markets on Wednesday, March 1, 2023.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2022, and provided an operating forecast and business updates.

Graphite Bio, Inc. announced that it has completed a review of its business, including the status of its programs, resources and capabilities.

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2022.

Poseida Therapeutics, Inc. today announced that the Company plans to highlight its clinical and preclinical pipeline progress during a virtual R&D Day to be held today at 10:00am ET / 7:00am PT.